Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-2004 in Atrial Fibrillation
NCT06280768Phase 1Completed
- Sponsor
- Beijing Suncadia Pharmaceuticals Co., Ltd.
- Start
- Apr 2024
- Primary completion
- Jan 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SHR-2004 in Atrial fibrillation (AFib), sponsored by Beijing Suncadia Pharmaceuticals Co., Ltd. Primary endpoint: Incidence and severity of adverse events up to 136 Days. Started Apr 2024; status: completed.
02
Drugs
SHR-2004
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NCT06280768.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06280768.